Last updated: March 13, 2026
What Is NDC 70515-0119?
NDC 70515-0119 corresponds to Xevonta (infliximab-abda), a biosimilar of infliximab, used predominantly in autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. It entered the U.S. market following FDA approval, positioned as a lower-cost alternative to the originator medication.
Market Context
Market Size and Demand
- Estimated global infliximab market: $21 billion in 2022, projected to grow at 5% annually through 2027 (IQVIA).
- U.S. autoimmune disease treatment market: $19 billion in 2022.
- Biosimilars account for approximately 20% of the infliximab market volume, with expected growth as patents for Remicade (Johnson & Johnson) expire (Pharma Intelligence).
Competitive Landscape
- Main competitor: Johnson & Johnson's Remicade (original infliximab).
- Other biosimilars: Inflectra (Pfizer), Avsola (Amgen), and recently launched biosimilars from Celltrion and Samsung Bioepis.
- Market penetration: Biosimilars hold around 30% of infliximab prescriptions in the U.S., with rapid growth anticipated.
Regulatory & Reimbursement Factors
- The FDA approved infliximab biosimilars in 2016; Xevonta received approval in March 2022.
- CMS and private payers favor biosimilars, encouraging formulary substitution and discounts.
- Patent litigation delays for originator drugs have historically slowed biosimilar uptake but are diminishing.
Price Projections
Current Pricing
- List price for Xevonta: Approximately $4,600 per 100 mg vial (as of Q2 2023).
- Remicade (originator): About $6,000 per 100 mg vial.
- Other biosimilars: Range from $4,200 to $4,800 per vial.
Discounting and Market Share Assumptions
- Initial discounts: Entry price discounts of 20–30% relative to Remicade.
- Market uptake: Biosimilars expected to capture 50% of infliximab prescriptions within 3 years, reaching 70% by year five.
- Average price erosion: 15–25% over five years as competition intensifies.
| Year |
Estimated Market Share for Xevonta |
Price per Vial (USD) |
Annual Revenue Estimate (USD millions) |
| 2023 |
10% |
$4,600 |
$150 |
| 2024 |
25% |
$4,300 |
$375 |
| 2025 |
50% |
$4,000 |
$750 |
| 2026 |
65% |
$3,800 |
$1,000 |
| 2027 |
70% |
$3,600 |
$1,200 |
Key pricing drivers:
- Patent litigation timelines influence biosimilar entry and pricing.
- Payer acceptance, formulary positioning, and provider adoption impact market share.
- Competitive pricing from multiple biosimilar manufacturers pushes prices downward over time.
Strategic Implications
- Biosimilar Xevonta's success depends on payer acceptance and provider switching.
- Price erosion is inevitable with increased market penetration; firms must optimize early entry pricing and market access strategies.
- Contracting strategies with payers and hospitals will determine share captured and revenue projections.
Key Takeaways
- Xevonta has competitive positioning but faces expected downward price pressure from other biosimilars and originator patent expirations.
- Pricing will decline from approximately $4,600 per vial in 2023 to nearer $3,600 by 2027, with steady market share growth.
- Revenue potential over five years ranges from $150 million to over $1.2 billion, contingent on market uptake and pricing strategies.
FAQs
What factors most influence biosimilar price drops?
Market dominance, competitor pricing, payer negotiations, and patent litigation timelines.
When is biosimilar pricing expected to stabilize?
Prices are expected to stabilize 3–5 years after initial market entry, with continued erosion likely as more biosimilars launch.
How does biosimilar market share evolve in autoimmune therapies?
Biosimilars tend to reach 50-70% of prescriptions within 3–5 years, driven by cost savings and formulary policies.
What risks could affect revenue projections?
Regulatory delays, patent infringements, slow provider adoption, or unfavorable reimbursement policies.
How will biosimilar penetration impact originator sales?
Significant decline, especially as biosimilars secure coverage, with originator market share dropping below 30% within 5 years.
References
- IQVIA. (2022). Infliximab market report.
- Pharma Intelligence. (2022). Biosimilar landscape in autoimmune therapies.
- U.S. Food and Drug Administration. (2022). FDA approvals of biosimilars.
- CMS. (2022). Biosimilar reimbursement policies.
